参芪扶正注射液配合化疗治疗消化道恶性肿瘤的临床观察

目的：验主参芪扶正注射液的临床疗效和安全性。方法；临床随机分３组，化疗加参芪组（简称治疗组，化疗加静脉滴注参芪拊正注射液）９９例，化疗对照组（简称化疗组，单用化疗）４５例，单纯参芪组（简称参芪组，单用参芪扶正注射液治疗）３８例。结果 治疗组缓解率为２０．２％，有效率为８７．９％，而化疗组分别为１５．６％和６８．９％，组间比较有显著性差异（Ｐ〈０．０５）；证候和生存质量的改善率，治疗组为７８．８％和

Clinical Study on Shenqi Fuzheng Injection Combined with Chemotherapy in Treating Malignant Tumor of Digestive Tract

OBJECTIVE: To assess the clinical effect and safety of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating malignant tumor of digestive tract. METHODS: One hundred and eighty-two patients were randomly divided into 3 groups, the combined therapy group (Group A), the SQFZI group (Group B) and the chemotherapy group (Group C). The remission and stabilization effect on cancer were observed. RESULTS: The remission rate and stabilizing rate of Group A were 20.2% and 87.9%, and those of the Group C were 15.6% and 68.9%, the difference between the two groups was significant, P < 0.05. The symptom and living quality improving rate of Group A were 78.8% and 42.4% separately, those of the Group B were 73.7% and 68.4% and of the Group C 37.8% and 26.7% respectively, the inter-group differences were significant, P < 0.05. The weight gain rate and effective rate of Group A were 45.5% and 90.9%, of Group C were 13.3% and 40.0%, P < 0.05. SQFZI showed good protective effect on hematopoietic system, 7.7% patients in Group A with WBC count lower than 4 x 10(9)/L after treatment, while in Group C, the percentage reached 22.2%. Moreover, SQFZI could raise activity of NK cell, macrophage and T-lymphcyte subgroups, without any injury on heart, liver and kidney function or other adverse reaction. CONCLUSION: SQFZI combined with chemotherapy has certain effect of remitting and stablizing on digestive tract tumor, the clinical effect is significant to patients with Qi-Deficiency, and is safe and reliable.